SEC Filing Summary: Synta Pharmaceuticals Corp. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Synta Pharmaceuticals Corp. on April 27, 2015, covering events occurring on April 22, 2015, and April 23, 2015. The filing addresses significant changes in executive leadership and board composition. Note: The request metadata referenced "Madrigal Pharmaceuticals," but the source text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Resignation of CEO: Anne Whitaker resigned as President, Chief Executive Officer, and member of the Board of Directors, effective May 7, 2015.
- Appointment of New CEO: Chen Schor, previously Executive Vice President and Chief Operating Officer, was appointed President and Chief Executive Officer, effective May 7, 2015.
- Board Appointment: Chen Schor was appointed as a Class I director, with a term expiring at the 2017 annual meeting of stockholders, effective May 7, 2015.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding business strategy. It notes that there are no undisclosed family relationships or related party transactions involving Mr. Schor. A press release detailing these changes was issued on April 27, 2015, and is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the effective date of leadership transition (May 7, 2015).
- Review the press release (Exhibit 99.1) for additional context on the resignation and appointment.
- Confirm Chen Schor's prior employment agreements referenced in the December 4, 2014, Form 8-K filing.
- Monitor subsequent filings for any financial impact related to executive compensation or severance arrangements.